JPRN-UMIN000005528招募中未知
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent glioma - Bevacizumab plus chemotherapy for children with recurrent glioma
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 20years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1)Patients taking anticoagulant agents 2)Patients with the past history of thrombosis 3)Patients with the past history of intestinal hemorrhage or lung hemorrhage 4)Past history of stereotactic radiosurgery for intracranial lesions may be included in exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. A phase 2 non-comparative randomized study. PRODIGE 41 - BEVANEC studyeuroendocrine carcinomaMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001305-16-FRHospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88
招募中
2 期
A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapyon-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000005486Hiroshima citizens hospital Department of Medical Oncology34
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE